Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YM087 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| YM087 | DRUG | - |
| YM087 oral | DRUG | - |
Inclusion Criteria: * Serum sodium levels 115 to \< 130mEq/L * Euvolemic or Hypervolemic hyponatremia Exclusion Criteria: * Clinical evidence of volume depletion or dehydration * Untreated severe hypothyroidism, hyperthyroidism, or adrenal insufficiency * Uncontrolled brady-or tachyarrhythmias re...
YM087 is an investigational small molecule being developed for the treatment of hyponatremia, a condition of abnormally low sodium levels in the blood. It is studied in patients with euvolemic or hypervolemic hyponatremia, meaning those with normal or excess fluid volume. The drug is in Phase 3 clinical development.
YM087 is being developed by Cumberland Pharmaceuticals Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol CPIX. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with hyponatremia.
YM087 is in Phase 3 clinical development for hyponatremia. Two Phase 3 trials have been completed, one evaluating an intravenous formulation and another evaluating an oral formulation. The drug is investigational and has not been approved by regulatory authorities.
YM087 has completed two Phase 3 clinical trials. NCT00380575 studied intravenous YM087 in 84 patients with euvolemic or hypervolemic hyponatremia in the United States, Canada, Israel, and South Africa. NCT00492037 studied oral YM087 in 83 patients across several European countries.
YM087 is a small molecule that targets the vasopressin receptor system to correct sodium imbalances in patients with hyponatremia. By modulating this pathway, it aims to increase serum sodium levels in individuals with euvolemic or hypervolemic hyponatremia.